Using PLX4032-resistant cell sublines, artificially derived from BRAF V600E-positive melanoma cell lines, key findings were validated in PLX4032-resistant tumors and in short-term cultures derived from patients involved in clinical trials. This evidence concerns the gene BRAF and melanoma.